Every respondent rejected the "add more AI" framing. The momentum already exists — the scheduling bot going from after-hours to 24/7, the RCM vendor live — but those are point wins without a method to measure, prioritize and scale them. The regulated-healthcare AI builder put it most sharply: the real problem is that there's no shared, ROI-ranked plan that leadership and the PE sponsor actually trust. The discovery-to-pilot shop framed it as needing "a methodology to ground any opportunities in their feasibility, timeline, and potential ROI" before chasing them; the PE-healthcare specialist, that there's "no systematic way to determine where the next dollar of AI investment should go or what return it will generate."
The sharpest analytic move — made independently by the regulated-healthcare builder, the discovery-to-pilot shop and the data-unification platform — is to treat the SG&A gap as the headline symptom but not the diagnosis. A real part of the work is separating genuinely addressable inefficiency from M&A integration debt and accounting differences, before anyone commits to savings. The data-unification platform went furthest, cautioning that part of the gap "may be an accounting artifact rather than real inefficiency" — a discipline worth holding onto when the number reaches the board.
Several respondents (the PE-healthcare specialist, the discovery-to-pilot shop, the cross-functional diagnostician) stressed building on the existing tools rather than around them: understand what's working before layering on more. The data-layer builder sharpened that into a warning — layering more isolated bots on top of the existing tools deepens fragmentation rather than fixing it. The lever, in their read, is a shared data/context layer, not a proliferation of point solutions you'll have to integrate later.
The consensus shape is consistent: weeks 1–2, shadow and map scheduling, prior auth, RCM, coding and finance, assess what the scheduling bot and RCM vendor handle today, and quantify the baseline — volumes, cycle times, FTE load, and where the SG&A gap actually lives. Weeks 3–4, quantify each opportunity, score effort vs. impact, and deliver a prioritized roadmap with an ROI target attached to each lever. Nearly everyone wants the sponsor's ROI metric (payback, FTE avoidance, throughput, margin) locked on day one and compliance in the room from week one, not the end.
The distinguishing move belongs to the regulated-healthcare builder and the data-layer builder: don't stop at a roadmap — build a contained proof-of-concept on the single highest-ROI lever to prove the number early and pressure-test data access. The regulated-healthcare builder is explicit that this de-risks the engagement before anyone commits to a fixed implementation price, citing a past healthcare project where untested EHR data access "became the long pole later."
Two firms named the breadth-vs-depth trap directly: cover all five workstreams at a screening level, then go deep on the two or three with the highest ROI. A surface-level pass at all five, the argument runs, produces a roadmap that reads complete but can't underwrite an investment decision. The implication: weight the firms that end the first month with a quantified, evidence-backed case on a real lever over those who end it with a comprehensive but shallow inventory.
The five diagnostic bids cluster tightly. The regulated-healthcare builder and the PE-healthcare specialist both come in at $50k; the data-layer builder's diagnostic phase is the lowest at $25–50k; the discovery-to-pilot shop is $80k; the cross-functional diagnostician is $75k, scaling with the number of functions in scope. All are fixed-fee and vendor-neutral — the platform owns the roadmap and decides what to build or buy next — and most explicitly offer to build what they recommend as a separate, later phase.
Two responses point past the roadmap. The data-layer builder offers a path to build a bespoke shared-data foundation in a HIPAA tenant (Phase 2, $75–150k to onboard plus a monthly platform fee in the low $10Ks) — the same firm can carry you from diagnostic into a custom platform, without forcing the decision up front. The data-unification platform is the genuinely different option: not a diagnostic at all, but a productized SaaS data platform ($350/month per location, all-in, plus a one-time onboarding fee) where the diagnostic and SG&A read fall out of standing the platform up. It isn't a like-for-like bid — but for a roll-up that will keep absorbing clinics, the proposition that "each new acquisition plugs into the same source of truth instead of becoming another integration project" is structurally different from a one-time roadmap, and worth weighing on its own terms.
| Expert | Engagement Model | Indicative Budget |
|---|---|---|
| Featured Expert A Regulated-healthcare AI builder |
Fixed-fee diagnostic + ROI roadmap with a contained proof-of-concept on the #1 lever. Implementation scoped separately. Vendor-neutral; you own the output. | $50k (Phase 1) ~6 wks; build phase separate |
| Featured Expert B PE-healthcare AI specialist |
Discovery diagnostic across all five workstreams, then deep on the 2–3 highest-ROI levers; produces implementation-ready specs. Builds what it recommends. | $50k ($30–75k range) 3–6 wks; build 2–3 mo |
| Featured Expert C Healthcare data-layer builder |
Phase 1 diagnostic + ROI-tagged roadmap, with an optional Phase 2 to build a custom shared-data/context platform. | Diagnostic $25–50k Platform: $75–150k + low-$10Ks/mo |
| Featured Expert D Discovery-to-pilot AI shop |
Structured discovery sprint + prioritized roadmap with pilot specs and a measurement framework to scale across acquisitions. Pilot build is Phase 2. | $80k (Phase 1) 6–8 wks; pilots 8–12 wks each |
| Featured Expert E Cross-functional AI diagnostician |
Diagnostic-only engagement: workflow maps, ROI model, use-case inventory (with HIPAA flags), build/buy/expand recommendations, exec readout. Implementation separate. | $75k scales with # functions in scope; 6–8 wks |
| Featured Expert F Data-unification platform · adjacent |
Productized SaaS data platform (subscription). Diagnostic, data foundation, dashboards and AI layer are part of going live — not a standalone build. Each new acquisition plugs into one source of truth. | $350/mo per location, all-in + one-time onboarding fee |
On a pure Phase-1 basis the roadmap bids span $25–80k, all reasonable for a diagnostic of this scope — the data-layer builder and the PE-healthcare specialist at the low end, the discovery-to-pilot shop and the cross-functional diagnostician at the top. The data-unification platform's per-location subscription can't be compared head-to-head; it trades a one-time fee for an ongoing capability, the right lens for an M&A roll-up rather than a single project cost.
The regulated-healthcare builder and the discovery-to-pilot shop flagged this independently: without clean baseline volumes, cost, and time data, ROI targets become estimates rather than commitments the sponsor will fund against. The mitigation is to lock the ROI metric on day one and use a proof-of-concept to prove one lever rather than assert savings across all five.
Acquired sites tend to run their own processes even on the same EHR, so "one automation" rarely drops cleanly into every location. Several respondents want process and data consistency checked early — and caution that automating on top of disconnected legacy systems can lock in complexity, so sequencing and integration may need to precede automation in places.
The most common failure mode in PE-backed healthcare AI diagnostics: a strong deliverable, but nothing gets built — the deck sits on a shelf because there's no clear next step or the team isn't equipped to execute. The field's mitigation is implementation-ready specs plus a contained POC, delivered by a firm able to build what it recommends.
In a PHI environment, BAAs and the security/compliance gatekeeper add real time to everything. Respondents were near-unanimous: bring that person in during week one and get sign-off as you go, rather than retrofitting governance at the end.
The core problem isn't "where could we use AI." It's that there's no shared, ROI-ranked plan that leadership and the PE sponsor actually trust. The upside is already proven in pockets (the scheduling bot from after-hours to 24/7, the RCM vendor live), but those are point wins without a framework to measure, prioritize and scale them. Meanwhile SG&A sits in the low-20s percent against comps in the high-single-to-low-teens range — some of that is structural M&A integration debt and some is genuinely automatable, and right now there's no clean way to tell which is which.
Before recommending a solution: where the SG&A gap actually lives (which workstreams, which sites); the real read/write access to the EHR and how the existing tools are integrated and measured today; what "ROI" means to the person signing the check; and the compliance posture — PHI handling, BAAs, and who the security gatekeeper is, involved from week one.
Week 1. Align leadership and the sponsor on the ROI metric and what success looks like. Bring security/compliance in immediately. Pull the systems inventory (EHR, scheduling bot, RCM vendor, finance stack) and line up SMEs.
Weeks 1–2. Shadow and map the current state across the five workstreams. Quantify the baseline — volumes, cycle times, FTE load, and where the SG&A gap concentrates.
Weeks 2–3. Build the opportunity inventory, score effort vs. impact, draft an ROI estimate per lever. Pick the #1 lever, scope a contained POC, and pressure-test data access for it.
Week 4. Build and validate the POC, firm up the future-state architecture and the crawl/walk/run roadmap, and pre-socialize findings with the sponsor so the final readout has zero surprises.
$50k for Phase 1 — the diagnostic, prioritized ROI roadmap, and a lightweight POC on the top lever. Not full implementation, which would be scoped separately once the levers are ranked and de-risked.
Roughly 6 weeks (compressible to ~4–5 if the workstream count is tightened), assuming timely SME access and reasonable read access to the EHR. Full implementation after the assessment would be a separate, larger phase.
1. ROI skepticism from the economic buyer. Seen on a near-identical engagement — momentum dies when a diagnostic ends in a clean deck instead of a business case the sponsor owns. Lock the ROI metric day one; use the POC to prove one lever.
2. M&A integration debt. Acquired sites run their own processes even on the same EHR, so "one automation" rarely drops in cleanly. Don't assume EHR data is accessible or clean until you've looked — a lesson from a past project where untested EHR access became the long pole.
3. Compliance bureaucracy. In a PHI environment, security and compliance gatekeepers add real time. Pull them in week one rather than saving it for the end.
A product and AI engineering firm with a repeatable AI Opportunity Assessment motion (shadow, map current state, score effort vs. impact, deliver a crawl/walk/run roadmap with an ROI model).
Reference engagement. A PE-backed healthcare-technology platform running utilization management: started with a fixed-fee assessment, then built a HIPAA-compliant "nurse-in-the-middle" assistant validated across 12 procedure types, modeling a 55% efficiency gain and $500k+ year-one savings with sub-1-year payback.
The company lacks a structured framework for identifying, quantifying and prioritizing AI opportunities across its clinical and administrative workflows. Individual initiatives have produced results (the scheduling bot expanded from after-hours to 24/7 on the strength of its performance), but there's no systematic way to determine where the next dollar of AI investment should go or what return it will generate. SG&A in the low-20s percent against comps in the high-single-to-low-teens range points to significant room, and every clinic added by M&A compounds the cost of the manual processes that come with it.
What we'd validate first: the clinical-vs-administrative split (where the largest opportunities sit); the current state of the scheduling bot and RCM vendor (build on what exists rather than start over); the EHR platform and degree of integration across acquired sites; and how leadership intends to use the roadmap — internal build decisions, vendor selection, or board-level investment approval — which shapes the depth and format of the deliverable.
Week 1. Map the core workflows across scheduling, prior auth, RCM, coding and finance. Understand what the scheduling bot and RCM vendor already handle and where gaps remain. Interview frontline staff and leadership to find where the most time and cost concentrate.
Week 2. Quantify each opportunity using the company's operational data. Build financial models tied to specific initiatives with conservative, moderate and aggressive scenarios.
Weeks 3–4. Deliver the prioritized roadmap with ROI targets, sequencing, and implementation specs for the top initiatives. Walk leadership through the findings and align on next steps — a clear, data-backed answer to "where should we invest in AI, in what order, and what should we expect in return."
$50k (true range $30–75k depending on scope and length). Discovery runs 3–6 weeks depending on breadth; full implementation engagements typically start at 2–3 months.
Deliverables: an initial discovery presentation to pick the first workflow(s); an ROI analysis of automating them and how the opportunity is underwritten; a proof-of-concept on the agreed workflow; and a fully built, integrated product if a full implementation is pursued. The diagnostic is designed to flow directly into a build.
1. Scope too broad. Cover the full landscape at a screening level, then go deep on the 2–3 opportunities with the highest ROI — a roadmap with ten initiatives and vague projections doesn't drive investment; three well-quantified ones with implementation plans do.
2. The roadmap has to lead somewhere. The common failure mode in PE-backed healthcare is a strong deliverable that nothing gets built from. Diagnostics are designed to produce implementation-ready specs, and the firm is available to build what it recommends.
An AI value-creation firm focused on PE-backed portfolio companies; a multi-billion-AUM fund recently made working with them a post-close mandate across its healthcare portfolio.
Reference engagement. AI document extraction for a PE-backed healthcare platform scaling from 1M to 2M+ patients — accuracy from <70% to 97%, with a projected $6–8M annual EBITDA impact; plus a behavioral-health portfolio audit that surfaced a $2.5M+ EBITDA opportunity and moved from discovery to build within weeks.
This isn't an "add more AI" problem — the scheduling bot and RCM vendor already prove the appetite. The core problem is that a fast M&A roll-up has its data and core workflows (scheduling, prior-auth, RCM, coding, finance) fragmented across the legacy systems of each acquired practice, with no unified source of truth and no framework to measure or scale value. The SG&A gap is the symptom; fragmentation and manual cross-site work are the cause. The real lever is a shared data/context layer plus a prioritized, ROI-tagged roadmap so the early wins become a system instead of islands.
What to validate first: which 2–3 workflows drive most of the SG&A gap; the true post-M&A systems map; clean baselines to attach real ROI targets; whether the scheduling bot and RCM vendor are scalable foundations or point tools to absorb; and the PHI/HIPAA boundaries that dictate the deployment model.
Weeks 1–2. Workflow deep-dives and a post-M&A systems/data map; interview ops, RCM and finance leads across a representative set of clinics/brands; pinpoint where manual time and cost concentrate; set baselines.
Weeks 3–4. Quantify the opportunity per workflow, prioritize by ROI and feasibility, confirm the PHI-safe deployment model, and deliver the roadmap + business case — plus a quick proof on the single highest-ROI workflow.
By day 30. A prioritized, ROI-tagged roadmap and a recommended first build.
Phase 1 — Diagnostic & ROI roadmap (~4–6 weeks): $25–50k. Workflow deep-dives, post-M&A systems map, quantified opportunity, prioritized roadmap with ROI per lever.
Phase 2 — Foundation build (within 12 weeks): $75–150k to onboard, plus a monthly platform fee in the low $10Ks. Stand up the shared context layer in a HIPAA tenant, integrate the top 1–2 ROI workflows first as proof, and fold in the existing bot/RCM vendor. Phase 2 is optional and scoped off the roadmap — the same firm can take you from diagnostic into a tailored platform if you want to go further.
1. Promising ROI before the systems are mapped. With multiple acquired brands on legacy platforms, savings estimates built on a fuzzy data picture won't hold — the systems map and clean baselines have to come before the targets.
2. Point-solution sprawl. Layering more isolated bots/vendors on top of the scheduling bot and RCM tool deepens fragmentation rather than fixing it; the roadmap should consolidate onto one layer, not proliferate tools you'll have to integrate later.
An applied-AI firm working in regulated, PHI environments, with a diagnostic-to-build motion that can extend into a custom data/context platform.
Reference engagement. An academic medical center oncology-surgery department — a scheduling-optimization and patient-access solution routing referrals to lift captured surgical revenue; plus a PHI de-identification and extraction pipeline that turned locked clinical records into analyzable data.
The core problem isn't adopting AI, but having a functioning framework and process to find, prioritize and measure automation value across the business. Momentum has already been built through the existing scheduling bot and RCM vendor, and the numbers — SG&A in the low-20s percent versus comps in the high-single-to-low-teens range — point to real administrative drag. With unlimited "opportunity" in AI, the priority is a methodology to ground opportunities in feasibility, timeline and ROI so time and resources go where the return is.
Before proposing a solution: clarify how much of the SG&A gap is actually addressable by automation versus accounting differences; whether baseline data exists to quantify ROI (workflow volumes, FTE time, cost per process); how fragmented the platforms are after acquisitions; and how the existing tools are performing today so the roadmap builds on them.
Week 1. Kickoff, align on priorities and success metrics, map stakeholders, set up data access and HIPAA terms.
Weeks 1–2. Map the five workflows through interviews and shadowing; assess where the existing tools are working or falling short.
Weeks 2–3. Quantify current-state cost and time to set the baseline and build the opportunity inventory.
Weeks 3–4. Score opportunities, surface quick wins, and draft the prioritized roadmap to pressure-test with leadership.
$80k for Phase 1 — the diagnostic and roadmap, inside the target quarter; pilot build and deploy follows as Phase 2, scoped from the roadmap (typically 8–12 weeks per pilot wave).
Deliverables: strategy and success-metric alignment; workflow deep-dives with current-state cost and time quantified; a prioritized opportunity inventory scored on impact and effort; an ROI model with a value target per lever; a phased roadmap sequenced for near-term wins; pilot specs for the top use cases; a measurement framework to track and scale gains across acquisitions; and a HIPAA/compliance check on candidate tools.
1. Data readiness. Without clean baseline volumes, cost and time data, ROI targets become estimates rather than commitments — early data access matters most.
2. Platform fragmentation from M&A. Automating on top of disconnected legacy systems can lock in complexity, so sequencing and integration sometimes need to come first.
3. Adoption. A related watch-out — gains only land if the workflows are actually used.
An AI strategy and build firm running a repeatable discovery-to-pilot methodology: align strategy, map workflows, prioritize use cases by impact and effort, produce ROI-targeted roadmaps, then take the top picks to live pilots.
Reference engagement. An online dermatology platform (HIPAA/PHI): built a custom agent that mapped every answer back to published, peer-reviewed studies — sharply higher accuracy than default LLMs on a deliberately noisy test set — plus an image-recognition version, across a compliant architecture touching PHI throughout.
The platform grew by acquisition, so the clinics run on different systems and nobody has one reliable view of how the business is performing — that's the thing to fix first. The scheduling bot and RCM vendor are good early wins, but you can't tell how much they're really saving, decide what to automate next, or roll a success across new sites, because the underlying data is scattered. Get scheduling, prior auth, RCM, coding and finance into one place so they become measurable; once the numbers are visible, the SG&A gap shows where the money is.
Before recommending anything: how many systems are really in play and how messy the data is; how the existing tools' results are tracked today; where SG&A actually sits by function and site — since part of the gap may be an accounting artifact rather than real inefficiency; and the PHI/governance rules now that it's all under one roof.
First couple of weeks. Talk to key stakeholders, inventory every source system and data flow, review what the existing tools do today, and nail down PHI/governance guardrails. Connect to priority systems and stand up a baseline metrics layer (SG&A by function and site, scheduling fill rates, RCM cycle and denial metrics).
By end of month. An early opportunity map ranking automation levers by ROI and effort, plus a couple of working dashboards so the team sees something real and data quality can be pressure-tested before committing to the full roadmap.
$350/month per active location, all-in (integrations, data modeling, reporting and the AI layer included), plus a one-time onboarding fee to stand up the data foundation and connect source systems. Delivered as a subscription, not a one-time project — the diagnostic, data foundation, dashboards and AI layer are all part of going live.
Total scales with how many clinics go live and how many source systems each requires. The output is the same prioritized, ROI-ranged roadmap the other firms propose — but it runs on a live platform that each new acquisition plugs into, rather than a one-time deliverable.
1. Data is messier than it looks after acquisitions. Underestimating cleanup is the usual reason these roadmaps stall — better to find out in week one than month three.
2. Don't jump into AI use cases before there's a baseline. Get the foundation right first, or you can't prove anything worked or justify the next spend.
Open questions: how consistent is the EHR across the sites, and how much appetite is there to consolidate tools versus just integrating what's already there?
A HIPAA-compliant, AI-powered data platform delivered as a subscription, built to unify multi-site operators onto one governed source of truth and benchmark them against comparable operators in its network.
Reference engagement. A PE-backed cosmetic-surgery roll-up — four practices across three CRMs and two EMRs unified into one HIPAA-compliant source of truth with AI monitoring and standardized 90-day forecasting; plus an aesthetics platform given an attribution layer across EMR, CRM and ad data that lowered patient acquisition cost.